Digital Health Integration Assessment and Maturity of U.S. Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Auto Injectable Devices (Preprint)

UNSTRUCTURED Auto injectable devices continue to provide real-life benefits for patients with chronic conditions since their widespread adoption 30 years ago with the rise of macromolecules. Nonetheless, issues surrounding adherence, patient administration techniques, disease self-management, and data outcomes at scale persist despite product design innovation. The interface of drug device combination products and digital health technologies formulates a value proposition for next generation auto injectable devices to power the delivery of precision care at home and achieve the full potential of biologics. Success will largely be dependent on biopharma's digital health maturity to implement this framework. This viewpoint measures the digital health maturity of the top 15 biopharmaceutical companies in the US biologics autoinjector market and establishes the framework for next generation auto injectables powering home-based precision care and need for formal digital health training.